Freemelt (FREEM) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Q2 2024 saw high activity in commercial and technical development, including the successful installation of the first eMELT industrial machine and a focus on tungsten and fusion applications.
Strategic collaborations and feasibility orders increased, especially in the U.S. defense and energy sectors, with new orders in North America and EMEA, including the first e-MELT®-iD order in North America and follow-up orders from UKAEA.
The company ramped up commercial efforts in North America and EMEA, leveraging partnerships to address capacity constraints and market education.
Accelerated demand in Defense, Energy, and MedTech sectors, with a focus on tungsten, copper, and titanium applications.
Operating result was -26,739 KSEK, lower than -22,890 KSEK in Q2 2023, due to delayed income and higher costs from intensified commercialization and product development.
Financial highlights
Net sales for Q2 were 2,410 KSEK, with two machine deliveries: one second-hand to University of Sheffield and one to Mid Sweden University, both at lower commercial value.
Aftermarket recurring revenues increased year-over-year, driven by a growing installed base.
Order book stood at 9,473 KSEK at quarter-end, rebounding from a Q1 slump.
Operating cash flow was SEK -11 million, impacted by higher inventory and receivables in preparation for future deliveries.
Cash at period end was 47,179 KSEK, boosted by a rights issue completed in May.
Outlook and guidance
The company expects continued growth in feasibility studies and machine orders, especially as commercial activities intensify and the U.S. team expands.
Sales cycles remain long (12–18 months), but a stronger pipeline and increased industry pull are expected to drive future machine sales.
Ahead of 2030 plan due to accelerated customer demand for feasibility studies and application development.
Continued focus on commercialization in Europe and North America, targeting industrial serial production.
No specific forecasts were provided, but management is optimistic about harvesting results from recent investments.
Latest events from Freemelt
- First industrial eMELT sale, OEM order, and machine sales growth amid ongoing losses.FREEM
Q3 20248 Jul 2026 - Record sales, fusion breakthroughs, and China entry drive growth in AM and medtech.FREEM
Investor Update1 Jul 2026 - Scaling up with 162% revenue growth, new funding, and global expansion in MedTech, defense, and fusion.FREEM
Investor update2 Jun 2026 - Q1 net sales rose 116% YoY, with strong margins and key sector collaborations advancing.FREEM
Q1 20265 May 2026 - Sales up 172% to SEK 54.5m, installed base up 40%, and strong growth in key sectors.FREEM
Q4 202519 Feb 2026 - Industrial 3D printing momentum grows, targeting SEK 1 billion sales by 2030.FREEM
ABGSC Investor Days11 Jan 2026 - Strong Q4 growth, major orders, and capital raise drive expansion in core sectors.FREEM
Q4 202423 Dec 2025 - Record Q2 sales and global expansion drive strong growth and order intake.FREEM
Q2 202523 Nov 2025 - Record order book and SEK 90M rights issue drive growth in defense, energy, and MedTech.FREEM
Q1 202521 Nov 2025